The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation

Cardiology (Switzerland)

Volumn 130, Issue 3, 2015, Pages 153-158

  Khand, Aleem U ^a,b   Chew, Pei G ^a   Douglas, Homeyra ^a   Jones, Julia ^a   Jan, Aftab ^b   Cleland, J G F ^c  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Atrial fibrillation; Heart failure; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIGOXIN; PLACEBO; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

AGED; ARTICLE; BRONCHOSPASM; CARDIAC PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIGITALIS INTOXICATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ATRIAL FIBRILLATION; CASE CONTROL STUDY; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL FIBRILLATION; BIOMARKERS; CARBAZOLES; CASE-CONTROL STUDIES; DIGOXIN; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROPANOLAMINES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 84923104273     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000368746     Document Type: Article

References (31)

1. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90:1765-1773.
2. Effects of carvedilol, a vasodilator beta-block-er, in patients with congestive heart failure due to ischaemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. Circulation 1995; 92:212-218.
3. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997; 349: 375-380.
4. Packer M, Bristow MR, Cohn JN, Colluci WS, Fowler MB, Gilbert EM, Shusterman NH: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334:1349-1355.
5. Khand AU, Rankin AC, Kaye G, Cleland JGF: Systematic review of the management of atri-al fibrillation in patients with heart failure. Eur Heart J 2000; 21:614-632.
6. Khand AU, Cleland JGF, Deedwania PC: Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev 2002; 7:267-283.
7. Jones JD, Khand AU, Douglas H, Ashrafi R, Shaw M, Cleland JG: The intersection of atri-al fibrillation and heart failure in a hospitalised population. Acta Cardiol 2013; 68:395-402.
8. Joglar JA, Acusta AP, Schusterman NH, Ra-maswamy K, Kowal R, Barbera SJ, et al: Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142:498-501.
9. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG: Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol 2003; 42: 1944-1951.
10. Rienstra M, Damman K, Mulder BA, Van Gelder IC, Mcmurray JJ, Van Veldhuisen DJ: Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013; 1:21-28.
11. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA: Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003; 41:2010-2017.
12. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H: B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010; 170:507-514.
13. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls M: Treatment of heart failure guided by plasma aminoterminal na-triuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.
14. Jourdain P, Jondeau G, Funck F, Gueffet P, Le HA, Donal E, Aupetit JF, Aumont MC, Gali-nier M, Eicher JC, Cohen-Solal A, Juilliere Y: Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007; 49:1733-1739.
15. Januzzi JL Jr, Rehman SU, Mohammed AA, Bhardwaj A, Barajas L, Barajas J, Kim HN, Baggish AL, Weiner RB, Chen-Tournoux A, Marshall JE, Moore SA, Carlson WD, Lewis GD, Shin J, Sullivan D, Parks K, Wang TJ, Gregory SA, Uthamalingam S, Semigran MJ: Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011; 58: 1881-1889.
16. Berger R, Moertl D, Peter S, Ahmadi R, Huels-mann M, Yamuti S, Wagner B, Pacher R: N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure: a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010; 55: 645-653.
17. Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, Fiuzat M, Stevenson LW, O'Connor CM: The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 2011; 17:613-621.
18. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Oster-hues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP: BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs. Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301:383-392.
19. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM: N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55:53-60.
20. Kawai K, Hata K, Takaoka H, Kawai H, Yo-koyama M: Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during beta-blocker therapy: a potential of hormone-guided treatment. Am Heart J 2001; 141:925-932.
21. Konishi M, Haraguchi G, Kimura S, Inagaki H, Kawabata M, Hachiya H, Hirao K, Isobe M: Comparative effects of carvedilol vs. biso-prolol for severe congestive heart failure. Circ J 2010; 74:1127-1134.
22. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Trawinski J, Amann-Zalan I, Hoersch S, Katus HA: NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 2004; 6: 343-350.
23. Yoshizawa A, Yoshikawa T, Nakamura I, Sa-toh T, Moritani K, Suzuki M, Baba A, Iwana-ga S, Mitamura H, Ogawa S: Brain natriuretic peptide response is heterogeneous during be-ta-blocker therapy for congestive heart failure. J Card Fail 2004; 10:310-315.
24. Davis ME, Richards AM, Nicholls MG, Yan-dle TG, Frampton CM, Troughton RW: Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006; 113: 977-985.
25. Meng F, Yoshikawa T, Baba A, Moritani K, Suzuki M, Satoh T, et al: Beta-blockers are effective in congestive heart failure patients with atrial fibrillation. J Card Fail 2003; 9:398-403.
26. Januzzi JL Jr: The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. Arch Cardiovasc Dis 2012; 105:40-50.
27. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H: Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998; 32:1839-1844.
28. Sanderson JE, Chan WW, Hung YT, Chan SKW, Shum IOL, Raymond K, Woo KS: Effect of low dose betablockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation va-sodilating betablocker. Br Heart J 1995; 74: 502-507.
29. Morello A, Lloyd-Jones DM, Chae CU, van Kimmenade RR, Chen AC, Baggish AL, O'Donoghue M, Lee-Lewandrowski E, Januzzi JL Jr: Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 2007; 153:90-97.
30. Inoue S, Murakami Y, Sano K, Katoh H, Shi-mada T: Atrium as a source of brain natri-uretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6:92-96.
31. Savarese G, Musella F, D'Amore C, Vassallo E, Losco T, Gambardella F, Cecere M, Petraglia L, Pagano G, Fimiani L, Rengo G, Leosco D, Trimarco B, Perrone-Filardi P: Changes of na-triuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis. JACC Heart Fail 2014; 2:148-158.